Udenaphil for treatment of erectile dysfunction in men. Literature review

І. І. Горпинченко, Ю. М. Гурженко


The work shows that Udenafil (ТМ Zydena) is one of the drugs of the selective IFE-5 group. The clinical properties of Udenafil are characterized by a relatively rapid onset of action and duration of the effect, which is explained by the pharmacokinetic profile of the drug. Udenafil is effective and well tolerated by patients in the treatment of ED, including ED associated with diabetes and other diseases. The drug is well tolerated and most side effects do not require drug withdrawal. Simultaneous use of antihypertensive agents or alpha-1-blockers does not affect the effectiveness and safety of Udenafil. Due to high safety profile, Udenafil can be recommended for daily regular use.


udenafil; Zydena; erectile dysfunction; therapy


Клінічна сексологія і андрологія / За ред. О.Ф. Возіанова, І.І. Горпинченка. – К.: Здоров’я, 1996. – 536 с.

Горпинченко И.И., Мирошников Я.О. Эректильная дисфункция. – 2003. – Л.: Медицина світу. – 85 с.

Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381(9861): 153–165.

Wessells H, Joyce GF, Wise M, Wilt TJ. Erectile dysfunction. J Urol. 2007;177(5):1675–1681.

Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot Res. 2003;15(1):63–71.

Kupelian V, Shabsigh R, Araujo AB, O’Donnell AB, McKinlay JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol. 2006;176(1):222–226.

McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol. 2005;47(6):838–845.

Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637–649.

Billups KL. Sexual dysfunction and cardiovascular disease: integrative concepts and strategies. Am J Cardiol. 2005;96(12B):57M–61M.

Brown JS, Wessells H, Chancellor MB, et al. Urologic complications of diabetes. Diabetes Care. 2005; 28(1): 177–185.

McVary KT. Clinical practice. Erectile dysfunction. N Engl J Med. 2007;357(24):2472–2481.

Kapur V, Chien CV, Fuess JE, Schwarz ER. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. Rev Cardiovasc Med. 2008;9(3):187–195.

Miner MM. Erectile dysfunction and the “window of curability”: a harbinger of cardiovascular events. Mayo Clin Proc. 2009;84(2): 102–104.

Shabsigh R, Shah M, Sand M. Erectile dysfunction and men’s health: developing a comorbidity risk calculator. J Sex Med. 2008;5(5): 1237–1243.

Hodges LD, Kirby M, Solanki J, O’Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007;61(12):2019–2025.

Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7(11):3572–3588.

Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013; 14(10): 1333–1344.

Bell AS, Palmer MJ. Novel phosphodiesterase type 5 modulators: a patent survey (2008–2010). Expert Opin Ther Pat. 2011;21(10):1631–1641.

Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63(5): 902–912.

Glina S, Toscano I, Gomatzky C, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med. 2009; 6(2):553–557.

Glina S, Fonseca GN, Bertero EB, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med. 2010;7(5):1928–1936.

Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs. 2008; 68(2): 231–250.

Doh H, Shin CY, Son M, et al. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res. 2002;25(6):873–878.

Paick JS, Kim SW, Yang DY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008; 5(4):946–953.

Park HJ, Park JK, Park K, Min K, Park NC. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. J Sex Med. 2010;7(6):2209–2216.

Moon DG, Yang DY, Lee CH, et al. A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. J Sex Med. 2011;8(7):2048–2061.

Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with

BPH/LUTS. Int J Impot Res. 2009; 21(2): 122–128.

Zhao C, Kim SW, Yang DY, et al. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2011; 60(2): 380–387.

Paick JS, Kim SW, Park YK, et al. The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents. J Sex Med. 2009;6(11):3166–3176.

Ortaз M, Зayan S, Зalisёkan MK, et al. Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study. Andrology. 2013; 1(4): 549–555.

Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002; 56(6): 453–459. 32. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342(24):1802–1813.

Kim NN. Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey. Int J Impot Res. 2003;15 Suppl 5:S13–S19.

Kim BH, Lim HS, Chung JY, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008;65(6):848–854.

Shim HJ, Kim YC, Park KJ, et al. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. J Pharm Sci. 2003;92(11):2185–2195.

Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999; 29(3): 297–310.

Kim TE, Kim BH, Kim JR, et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2009;68(1):43–46.

Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999;83(5A): 3C–12C.

Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol. 2001; 65:1–52.

Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 2004; 16(Suppl 1):S11–S14.

Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE#5 inhibitors sildenafil, vardenafil and tadalafil – review of the literature. Eur J Med Res. 2002;7(10):435–446.

Ku HY, Ahn HJ, Seo KA, et al. The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008;36(6):986–990.

Ji HY, Lee HW, Kim HH, et al. Role of human cytochrome P450 3A4 in the metabolism of DA#8159, a new erectogenic. Xenobiotica. 2004; 34(11–12): 973–982.

Kim J, Kim SJ, Ji HY, et al. Simultaneous determination of a new phosphodiesterase-5 inhibitor DA-8159 and its active metabolite in human plasma by high performance liquid chromatography with tandem mass spectrometry. Chromatographia. 2003; 57(7–8): 447–450.

Amakye D, Ward J, Bryson S, Han K. DA-8159-phase I studies to investigate the safety and pharmacokinetics in healthy male Caucasian subjects. Clin Pharmacol Ther. 2004;75:86.

Hatzichristou D, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010; 57(5): 804–814.

Oh TY, Kang KK, Ahn BO, Yoo M, Kim WB. Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res. 2000;23(5):471–476.

Salem EA, Kendirci M, Hellstrom WJ. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs. 2006; 7(7): 661–669.

Ding H, Du W, Wang H, et al. Efficacy and safety of udenafil for erectile dysfunction: a meta-analysis of randomized controlled trials. Urology. 2012;80(1):134–139.

Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complications. 2011;25(2):129–136.

Kang KK, Choi SM, Ahn GJ, Kwon JW, Kim WB. The effect of DA-8159 on corpus cavernosal smooth muscle relaxation and penile erection in diabetic rabbits. Urol Res. 2004; 32(2): 107–111.

Ahn GJ, Sohn YS, Kang KK, et al. The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats. Int J Impot Res. 2005;17(2):134–141.

Ahn GJ, Yu JY, Choi SM, et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl. 2005; 28(5):260–266.

Ahn GJ, Chung HK, Lee CH, Kang KK, Ahn BO. Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis. Asian J Androl. 2009;11(4):435–442.

Cho SY, Park K, Paick JS, Kim SW. Change of erectile function and responsiveness to phosphodiesterase type 5 inhibitors at different stages of streptozotocin-induced diabetes in rats. J Sex Med. 2011;8(5): 1352–1361.

Martнnez-Salamanca JI, Carballido J, Eardley I, et al. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Eur Urol. 2011; 60(3): 527–535.

Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with б-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012; 61(5): 994–1003.

Blonde L. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. Curr Med Res Opin. 2006;22(11): 2111–2120.

Kloner RA, Sadovsky R, Johnson EG, Mo D, Ahuja S. Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. Int J Impot Res. 2005;17(5):450–454.

Shabsigh R, Duval S, Shah M, Regan TS, Juhasz M, Veltry LG. Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data. Curr Med Res Opin. 2007;23(10):2453–2460.

Giuliano F, Vicaut E, Jeanpetit Y. Impact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse interval. Prog Urol. 2008;18:536–542.

Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2002;53 Suppl 1:61S–65S.

Zinner N. Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study. J Sex Med. 2007;4:137–144.

Moncada I, Jara J, Subirб D, Castaсo I, Hernбndez C. Efficacy of sildenafil citrate at 12 hours after dosing: Re-exploring the therapeutic window. Eur Urol. 2004;46:357–360.

Інструкція для медичного застосування препарату Зидена РП NoUA /15216/01/01, UA/15216/01/02 від 03.06.2016 No520.

Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol. 2009;55(2):334–347.

Lee CH, Kim HS, Goo MJ, et al. Chronic administration of udenafil, a selective phosphodiesterase type 5 inhibitor, promotes erectile function recovery in an animal model of bilateral cavernous nerve crush injury. J Sex Med. 2011;8(5):1330–1340.

Lee CH, Shin JH, Ahn GJ, Kang KK, Ahn BO, Yoo M. Udenafil enhances the recovery of erectile function and ameliorates the pathophysiological consequences of cavernous nerve resection. J Sex Med. 2010;7(7):2564–2571.

Kim I, Kim D. Anterior ischemic optic neuropathy associated with udenafil. Korean J Ophthalmol. 2012; 26(3): 235–238.

Kim MG, Kim JR, Kim BH, et al. The effect of udenafil on the hemodynamics of healthy male volunteers administered tamsulosin. Curr Med Res Opin. 2013;29(6):685–693.

Berner MM, Kriston L, Harms A. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. Int J Impot Res. 2006; 18(3):229–235.

Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev. 2007; (1):CD002187

Sбenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 2002; 25(12): 2159–2164.

Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26(3): 777–783.

Copyright (c) 2020 І. І. Горпинченко, Ю. М. Гурженко

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN 2412-5547 (Online), ISSN 2307-5090 (Print)